Based on further analysis of immune-activating and immune-inhibitory gene expression patterns in PBMCs, the authors suggested four immunological subgroups; all healthy subjects were in the “lymphocyte retention group” (upregulated CD8A, CD4, CD248, IDO1, IDO2), while BC patients were in “monocyte activating” (upregulated CD14, CD40, CD80, Siglec14, NRP1, TIM3), “T-cell inhibitory” (upregulated PD-L1, PD1, CTLA4, FOXP3, CCR3), or “unknown” group. This evidence concerns the gene CD274 and breast cancer.